SEC Form SC 13G/A filed by ProQR Therapeutics N.V. (Amendment)

2/9/23 12:31:03 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $PRQR alert in real time by email

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.1 PROQR THERAPEUTICS NV COMMON STOCK Cusip #N71542109 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #N71542109 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 0 Item 6: 0 Item 7: 0 Item 8: 0 Item 9: 0 Item 11: 0.000% Item 12: HC Cusip #N71542109 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 0 Item 8: 0 Item 9: 0 Item 11: 0.000% Item 12: IN Item 1(a). Name of Issuer: PROQR THERAPEUTICS NV Item 1(b). Address of Issuer's Principal Executive Offices: ZERNIKEDREEF 9 LEIDEN, P7 2333 CK Netherlands Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: N71542109 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 0 (b) Percent of Class: 0.000% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 0 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof, the reporting person has ceased to be the beneficial owner of any of the class of securities, check the following (X). Item 6. Ownership of More than Five Percent on Behalf of Another Person. Not applicable. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing orinfluencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. February 9, 2023 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on February 9, 2023, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of PROQR THERAPEUTICS NV at December 30, 2022. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January, 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Get the next $PRQR alert in real time by email

Recent Analyst Ratings for

$PRQR

Date	Price Target	Rating	Analyst
3/12/2026	$9.00	Outperform	Oppenheimer
4/29/2025	$5.00	Outperform	Evercore ISI
4/29/2025	$8.00	Overweight	Cantor Fitzgerald
3/10/2025	$4.00	Neutral → Buy	Citigroup
1/10/2025	$15.00	Outperform	Oppenheimer
10/29/2024	$6.00 → $14.00	Outperform → Strong Buy	Raymond James
11/8/2023	$2.00	Neutral → Buy	Chardan Capital Markets
3/30/2023	$1.50 → $5.00	Mkt Perform → Mkt Outperform	JMP Securities

More analyst ratings

SEC Form SC 13G/A filed by ProQR Therapeutics N.V. (Amendment)

2/9/23 12:31:03 PM ET

$PRQR

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $PRQR alert in real time by email

Recent Analyst Ratings for

$PRQR

Date	Price Target	Rating	Analyst
3/12/2026	$9.00	Outperform	Oppenheimer
4/29/2025	$5.00	Outperform	Evercore ISI
4/29/2025	$8.00	Overweight	Cantor Fitzgerald
3/10/2025	$4.00	Neutral → Buy	Citigroup
1/10/2025	$15.00	Outperform	Oppenheimer
10/29/2024	$6.00 → $14.00	Outperform → Strong Buy	Raymond James
11/8/2023	$2.00	Neutral → Buy	Chardan Capital Markets
3/30/2023	$1.50 → $5.00	Mkt Perform → Mkt Outperform	JMP Securities

More analyst ratings

SEC Form SC 13G/A filed by ProQR Therapeutics N.V. (Amendment)

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$PRQR

SEC Form SC 13G/A filed by ProQR Therapeutics N.V. (Amendment)

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$PRQR

$PRQR
Press Releases

ProQR Announces First Quarter 2026 Operating and Financial Results

ProQR Announces Multiple Upcoming Scientific Conference Presentations Highlighting the Breadth of its Axiomer™ RNA Editing Platform

ProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026

$PRQR
Analyst Ratings

Oppenheimer resumed coverage on ProQR Therapeutics with a new price target

Evercore ISI initiated coverage on ProQR Therapeutics with a new price target

Cantor Fitzgerald resumed coverage on ProQR Therapeutics with a new price target

$PRQR
Insider Trading

SEC Form 4 filed by Director Hinsch Gylvin Lykke

SEC Form 3 filed by new insider Hinsch Gylvin Lykke

SEC Form 3 filed by new insider Valerio Domenico

$PRQR
SEC Filings

SEC Form 6-K filed by ProQR Therapeutics N.V.

SEC Form 6-K filed by ProQR Therapeutics N.V.

SEC Form 6-K filed by ProQR Therapeutics N.V.

$PRQR
Financials

ProQR Therapeutics to Host Virtual Analyst and Investor Event on December 11, 2024

ProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer™ RNA Editing Program Targeting NTCP for Cholestatic Diseases

ProQR Announces Conference Call to Discuss Axiomer® RNA Editing Platform

$PRQR
Large Ownership Changes